XML 40 R9.htm IDEA: XBRL DOCUMENT
v3.22.2

Revenues | 6 Months Ended
--- | ---
Jun. 30, 2022
Revenue from Contract with Customer [Abstract] |
Revenues | Product Revenue Revenue by product is summarized as follows:
|  | For the Three Months Ended June 30,
|  | 2022 |  | 2021
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA |  | $ | 120.7 |  |  | $ | 277.2 |  |  | $ | 397.9 |  |  | $ | 178.4 |  |  | $ | 309.2 |  |  | $ | 487.6 |
VUMERITY(1) |  | 129.9 |  |  | 6.9 |  |  | 136.8 |  |  | 90.7 |  |  | 0.2 |  |  | 90.9 |
Total Fumarate |  | 250.6 |  |  | 284.1 |  |  | 534.7 |  |  | 269.1 |  |  | 309.4 |  |  | 578.5 |
AVONEX |  | 171.0 |  |  | 87.7 |  |  | 258.7 |  |  | 214.0 |  |  | 96.9 |  |  | 310.9 |
PLEGRIDY |  | 40.2 |  |  | 51.3 |  |  | 91.5 |  |  | 43.4 |  |  | 46.1 |  |  | 89.5 |
Total Interferon |  | 211.2 |  |  | 139.0 |  |  | 350.2 |  |  | 257.4 |  |  | 143.0 |  |  | 400.4 |
TYSABRI |  | 291.9 |  |  | 224.3 |  |  | 516.2 |  |  | 299.8 |  |  | 224.4 |  |  | 524.2 |
FAMPYRA |  | — |  |  | 25.5 |  |  | 25.5 |  |  | — |  |  | 26.1 |  |  | 26.1 |
Subtotal: MS |  | 753.7 |  |  | 672.9 |  |  | 1,426.6 |  |  | 826.3 |  |  | 702.9 |  |  | 1,529.2 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 139.8 |  |  | 291.3 |  |  | 431.1 |  |  | 149.3 |  |  | 350.4 |  |  | 499.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 115.8 |  |  | 115.8 |  |  | — |  |  | 121.5 |  |  | 121.5 |
IMRALDI |  | — |  |  | 57.6 |  |  | 57.6 |  |  | — |  |  | 55.6 |  |  | 55.6 |
FLIXABI |  | — |  |  | 20.5 |  |  | 20.5 |  |  | — |  |  | 25.3 |  |  | 25.3 |
BYOOVIZ(2) |  | 0.5 |  |  | — |  |  | 0.5 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilars |  | 0.5 |  |  | 193.9 |  |  | 194.4 |  |  | — |  |  | 202.4 |  |  | 202.4 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 2.7 |  |  | 2.7 |  |  | — |  |  | 3.1 |  |  | 3.1 |
ADUHELM |  | 0.1 |  |  | — |  |  | 0.1 |  |  | 1.6 |  |  | — |  |  | 1.6 |
Total product revenue |  | $ | 894.1 |  |  | $ | 1,160.8 |  |  | $ | 2,054.9 |  |  | $ | 977.2 |  |  | $ | 1,258.8 |  |  | $ | 2,236.0 |
(1) VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021. (2) BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.
|  | For the Six Months Ended June 30,
|  | 2022 |  | 2021
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA |  | $ | 237.8 |  |  | $ | 570.0 |  |  | $ | 807.8 |  |  | $ | 340.8 |  |  | $ | 626.0 |  |  | $ | 966.8 |
VUMERITY(1) |  | 255.1 |  |  | 9.7 |  |  | 264.8 |  |  | 164.3 |  |  | 0.3 |  |  | 164.6 |
Total Fumarate |  | 492.9 |  |  | 579.7 |  |  | 1,072.6 |  |  | 505.1 |  |  | 626.3 |  |  | 1,131.4 |
AVONEX |  | 319.0 |  |  | 169.3 |  |  | 488.3 |  |  | 423.2 |  |  | 198.8 |  |  | 622.0 |
PLEGRIDY |  | 74.5 |  |  | 97.0 |  |  | 171.5 |  |  | 76.0 |  |  | 102.9 |  |  | 178.9 |
Total Interferon |  | 393.5 |  |  | 266.3 |  |  | 659.8 |  |  | 499.2 |  |  | 301.7 |  |  | 800.9 |
TYSABRI |  | 576.4 |  |  | 460.6 |  |  | 1,037.0 |  |  | 573.1 |  |  | 454.4 |  |  | 1,027.5 |
FAMPYRA |  | — |  |  | 51.7 |  |  | 51.7 |  |  | — |  |  | 52.7 |  |  | 52.7 |
Subtotal: MS |  | 1,462.8 |  |  | 1,358.3 |  |  | 2,821.1 |  |  | 1,577.4 |  |  | 1,435.1 |  |  | 3,012.5 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 303.1 |  |  | 600.5 |  |  | 903.6 |  |  | 298.0 |  |  | 722.2 |  |  | 1,020.2 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 230.5 |  |  | 230.5 |  |  | — |  |  | 243.2 |  |  | 243.2 |
IMRALDI |  | — |  |  | 114.7 |  |  | 114.7 |  |  | — |  |  | 113.5 |  |  | 113.5 |
FLIXABI |  | — |  |  | 43.0 |  |  | 43.0 |  |  | — |  |  | 50.8 |  |  | 50.8 |
BYOOVIZ(2) |  | 0.5 |  |  | — |  |  | 0.5 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilars |  | 0.5 |  |  | 388.2 |  |  | 388.7 |  |  | — |  |  | 407.5 |  |  | 407.5 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 4.9 |  |  | 4.9 |  |  | — |  |  | 5.9 |  |  | 5.9 |
ADUHELM |  | 2.9 |  |  | — |  |  | 2.9 |  |  | 1.6 |  |  | — |  |  | 1.6 |
Total product revenue |  | $ | 1,769.3 |  |  | $ | 2,351.9 |  |  | $ | 4,121.2 |  |  | $ | 1,877.0 |  |  | $ | 2,570.7 |  |  | $ | 4,447.7 |
(1) VUMERITY became commercially available in the E.U. during the fourth quarter of 2021. (2) BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022. We recognized revenue from two wholesalers accounting for 27.4% and 11.2% of gross product revenue for the three months ended June 30, 2022, and 26.8% and 10.8% of gross product revenue for the six months ended June 30, 2022. We recognized revenue from two wholesalers accounting for 30.2% and 9.9% of gross product revenue for the three months ended June 30, 2021, and 30.1% and 9.6% of gross product revenue for the six months ended June 30, 2021. An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, December 31, 2021 |  | $ | 137.7 |  |  | $ | 759.6 |  |  | $ | 38.0 |  |  | $ | 935.3 |
Current provisions relating to sales in current year |  | 337.7 |  |  | 1,346.1 |  |  | 6.4 |  |  | 1,690.2 |
Adjustments relating to prior years |  | (1.1) |  |  | (58.6) |  |  | (4.6) |  |  | (64.3) |
Payments/credits relating to sales in current year |  | (243.8) |  |  | (833.3) |  |  | — |  |  | (1,077.1) |
Payments/credits relating to sales in prior years |  | (98.4) |  |  | (391.3) |  |  | (10.6) |  |  | (500.3) |
Balance, June 30, 2022 |  | $ | 132.1 |  |  | $ | 822.5 |  |  | $ | 29.2 |  |  | $ | 983.8 |
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) |  | As of June 30, 2022 |  | As of December 31, 2021
Reduction of accounts receivable |  | $ | 137.8 |  |  | $ | 133.2 |
Component of accrued expense and other |  | 846.0 |  |  | 802.1 |
Total revenue-related reserves |  | $ | 983.8 |  |  | $ | 935.3 |
Revenue from Anti-CD20 Therapeutic Programs Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 139.9 |  |  | $ | 178.8 |  |  | $ | 283.1 |  |  | $ | 352.9 |
OCREVUS and other revenue from anti-CD20 therapeutic programs |  | 296.4 |  |  | 261.2 |  |  | 552.6 |  |  | 476.1 |
Total revenue from anti-CD20 therapeutic programs |  | $ | 436.3 |  |  | $ | 440.0 |  |  | $ | 835.7 |  |  | $ | 829.0 |
For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in our 2021 Form 10-K. Other Revenue Other revenue is summarized as follows:
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Revenue from collaborative and other relationships: |  |  |  |  |  |  |  |
Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis |  | $ | 6.4 |  |  | $ | 5.5 |  |  | $ | 14.4 |  |  | $ | 9.4 |
Other royalty and corporate revenue: |  |  |  |  |  |  |  |
Royalty |  | 10.3 |  |  | 6.4 |  |  | 20.9 |  |  | 12.6 |
Other corporate |  | 81.2 |  |  | 87.1 |  |  | 128.7 |  |  | 170.3 |
Total other revenue |  | $ | 97.9 |  |  | $ | 99.0 |  |  | $ | 164.0 |  |  | $ | 192.3 |
We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration